The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Copenhagen
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (functional MRI)
Study Overview
Brief Summary
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.
Detailed Description
Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2).
MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 20 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Type 2 diabetes
- •BMI 20-35 kg/m^2
- •Age 20-80
Exclusion Criteria
- •Not MRI-compatible implants
- •Claustrophobia
- •Abnormal kidney or liver function
- •Planned weight loss or change in diet
- •Hypertension
- •Other conditions that could be expected to affect the primary or secondary outcomes
Arms & Interventions
Saline and oral water (SAL-WAT)
Saline infusion, oral water ingestion
Intervention: Saline / placebo (Other)
Saline infusion and oral glucose ingestion (SAL-GLU)
Saline infusion, oral glucose ingestion
Intervention: Saline / placebo (Other)
GIP(3-30)NH2 infusion and oral water ingestion (GIA-WAT)
GIPR antagonist infusion, oral water ingestion
Intervention: GIPR antagonist / study tool (Other)
GIP(3-30)NH2 infusion and oral glucose ingestion (GIA-GLU)
GIPR antagonist infusion, oral glucose ingestion
Intervention: GIPR antagonist / study tool (Other)
Outcomes
Primary Outcomes
Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (functional MRI)
Time Frame: 80 minutes
Measued with phase-contrast MRI in ml/min
Secondary Outcomes
- GIP(3-30)NH2 levels(80 minutes)
- Glucose(80 minutes)
- C-peptide(80 minutes)
- Glucagon(80 minutes)
- Insulin(80 minutes)
- Blood flow in portal vein(80 minutes)
- Blood flow in hepatic artery(80 minutes)
- Blood flow in coeliac trunc(80 minutes)
- GIP levels(80 minutes)